Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Stefan Wheat

General Emergency Medicine · UW

View

Dr. Ryan Stanton

General Emergency Medicine · ACEP

View

Dr. Jim Dahle

General Emergency Medicine · The White Coat Investor

View

Dr. Mohamed Hagahmed

General Emergency Medicine · University of Pittsburgh

View

Dr. Sorabh Khandelwal

General Emergency Medicine · OSU

View

Dr. Jennifer Wiler

General Emergency Medicine · UCD

View

Dr. Gita Pensa

General Emergency Medicine · Brown University

View

Dr. Heidi Best

General Emergency Medicine · Emergency Physicians of Tidewater

View

Dr. Kimberly Chernoby

General Emergency Medicine · GW

View

Dr. Amal Mattu

General Emergency Medicine · UMSOM

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Scientific Priorities Related to the Use of Double Sequential External Defibrillation in Patients With Refractory Cardiac Arrest: Report From a Multistakeholder Thinktank.

    Nov 3, 2025DOI: 10.1161/jaha.125.044130Journal ArticleAHA

    Written by: Graham NicholDianne L AtkinsRudolph W KosterPeter J KudenchukJosé G CabañasDouglas F KupasRemle CroweFred ChapmanJason BartosCharles D DeakinMarina Del RiosAnnemarie SilverDawn JorgensonComilla SassonMitchell Krucoff

    Find these authors on Roon

    CS
    Dr. Comilla Sasson
    General Emergency Medicine · CU Anschutz Medical Campus

    DEFINITION OF RECURRENT AND REFRACTORY VF

    The primary objective of VF therapy is termination of VF resulting in ROSC. Initial defibrillation and serial defibrillation attempts may be successful, temporarily successful, or unsuccessful. In the immediate aftermath of shock, assessment of postdefibrillation rhythm may be obscured for 2 to 3 seconds by residual hyperpolarization in the defibrillator pads. Resumption of chest compressions further obscures assessment of rhythm due to CPR artifact and limits rhythm interpretation until CPR is later paused for rhythm analysis and pulse check. The persistent or transient success or complete failure of shock in terminating VF is difficult to assess until the end of this 2‐minute postshock CPR period and not possible during use of an automated external defibrillator, unless it has specialized software. Historically commonly accepted definitions used to assess interventions in OHCA VF include: Successful defibrillation: any nonshockable rhythm (asystole or organized electrical activity) observed 5 seconds after delivery of a defibrillation shock for VF.Unsuccessful defibrillation: VF observed 5 seconds after delivery of a defibrillation shock.Recurrent VF: Return of VF after confirmed successful earlier defibrillation.Refractory VF: Ventricular fibrillation that is not terminated with any of 3 initial shocks.Pragmatic definition of refractory VF: VF that is visible at the rhythm check that is done 2 minutes after a third attempted defibrillation with or without confirmation of unsuccessful defibrillations at any of the previous 3 defibrillation shocks.Successful defibrillation: any nonshockable rhythm (asystole or organized electrical activity) observed 5 seconds after delivery of a defibrillation shock for VF.Unsuccessful defibrillation: VF observed 5 seconds after delivery of a defibrillation shock.Recurrent VF: Return of VF after confirmed successful earlier defibrillation.Refractory VF: Ventricular fibrillation that is not terminated with any of 3 initial shocks.Pragmatic definition of refractory VF: VF that is visible at the rhythm check that is done 2 minutes after a third attempted defibrillation with or without confirmation of unsuccessful defibrillations at any of the previous 3 defibrillation shocks.
    Among patients with an initial VF treated with a contemporary biphasic defibrillator, the reported rate of conversion to another rhythm after a first shock was >90%. For the <10% of patients with refractory VF after a first shock, success rates of subsequent shocks declined, but even after 5 shocks, success rates were >80%. With devices that had escalating energy (ie, did not give first shock at their highest energy), defibrillation success correlated with an increase to higher shock energy with subsequent shocks.10 The incidence of VF refractory to defibrillation was thus skewed, with only 5% of all patients accounting for 71% of unsuccessful defibrillations.11 Of the different types of VF observed after shock described previously, the incidence of unsuccessful defibrillation (ie, persistent shock‐refractory VF) is least common.
    In another cohort study, recurrent VF was reported in 50% to 60% of all cases, a median of 30 to 60 seconds after a first or later defibrillation shock.12 In additional studies, >3 shocks were needed in 42% to 45% of patients before ROSC was achieved.13, 14, 15, 16 The majority of these shocks were successful, but recurrence of VF made >3 shocks necessary. The probability that 3 consecutive shocks were all unsuccessful was rare. Among patients who received at least 3 shocks, only 5% remained in VF after the third shock.17 Because <25% of patients with OHCA have a first recorded shockable rhythm, about 1.25% of all patients with OHCA treated by EMS will have refractory VF. Taken together, these studies thus suggest that among a patient cohort defined using a pragmatic definition of refractory VF, mechanistically the VF treated is most likely to be recurrent rather than truly refractory.

    CURRENT GUIDELINES FOR RECURRENT AND REFRACTORY VF

    The AHA Emergency Cardiovascular Care Committee and International Liaison Committee on Resuscitation are charged with reviewing relevant science and making treatment recommendations related to emergency cardiac care. The 2020 AHA Emergency Cardiac Care Guidelines treatment recommendation related to DSED state18: The usefulness of [DSED] for refractory shockable rhythm has not been established.It is anticipated that this recommendation will be updated in 2025.
    The usefulness of [DSED] for refractory shockable rhythm has not been established.
    It is anticipated that this recommendation will be updated in 2025.
    As of November 8, 2023, International Liaison Committee on Resuscitation Consensus on Science with Treatment Recommendations state19:We suggest that a [DSED] strategy (weak recommendation, low‐certainty evidence) or a VC defibrillation strategy (weak recommendation, very low–certainty evidence) may be considered for adults with cardiac arrest who remain in VF or pulseless ventricular tachycardia after ≥3 consecutive shocks. If a [DSED] strategy is used, we suggest an approach similar to that in the available trial, with a single operator activating the defibrillators in sequence (good practice statement).
    We suggest that a [DSED] strategy (weak recommendation, low‐certainty evidence) or a VC defibrillation strategy (weak recommendation, very low–certainty evidence) may be considered for adults with cardiac arrest who remain in VF or pulseless ventricular tachycardia after ≥3 consecutive shocks. If a [DSED] strategy is used, we suggest an approach similar to that in the available trial, with a single operator activating the defibrillators in sequence (good practice statement).
    Another well‐discussed aspect of AHA Emergency Cardiac Care Guidelines relevant to therapy of patients with OHCA and VF was that in 2005, the guidelines recommended immediate resumption of CPR after shock, delaying a reanalysis of rhythm or pulse check until after 2 minutes of CPR rather than immediately after each shock, to avoid long pauses in chest compressions.20 While minimizing interruption of chest compressions, a delayed analysis of the postshock rhythm, which is obscured during the interim period by CPR artifact, compromises the ability to distinguish recurrent VF from refractory VF. Thus, the pragmatic clinical definition of refractory VF, which is discussed later, has emerged as a consequence of these changes in the 2005 AHA guidelines.

    CRITICAL APPRAISAL OF THE CLINICAL SCIENCE OF DSED FOR VF

    DSED involves the sequential delivery of 2 separate defibrillation shocks from 2 defibrillators placed in different positions. Typically, this is performed when a patient remains in VF after multiple standard defibrillation attempts. Proposed physiologic bases of DSED are: Additive probability: Defibrillation is probabilistic.21 Individuals shocks of equal strength will sometimes succeed and at other times fail to defibrillate in a chance‐like fashion. When 2 shocks are delivered over a short time, the probabilities of those 2 shocks could be additive so as to increase the probability of successful defibrillation.22 The cumulative strength and temporal proximity of a closely spaced second shock could terminate VF when the first shock did not. Conversely, if the first shock converted VF, a second shock could induce a relapse of the recently terminated arrhythmia.Different shock vectors affect different parts of the myocardium: Each shock from the surface of the chest sends current through the chest, resulting in variable current or energy delivered across the myocardium,23 depending on electrode positions, body habitus, and other factors. In parts of the heart where the electric field is strong enough, it interacts with myocytes to produce a desired effect (eg, to cause or extend refractoriness to VF). If an anterior‐lateral shock is inadequate for defibrillation, administering a second shock from a different vector shortly thereafter could provide an electric field strong enough in regions of the heart where the first shock was too weak to have the desired effect on myocytes,24 thereby enabling the therapy to affect a critical mass of myocardium.22, 25, 26Stepwise defibrillation, sometimes referred to as multistage electrotherapy: The first shock serves to decrease the complexity of the VF, reducing the defibrillation threshold so that the second shock is more likely to successfully terminate the arrhythmia.27, 28, 29
    Additive probability: Defibrillation is probabilistic.21 Individuals shocks of equal strength will sometimes succeed and at other times fail to defibrillate in a chance‐like fashion. When 2 shocks are delivered over a short time, the probabilities of those 2 shocks could be additive so as to increase the probability of successful defibrillation.22 The cumulative strength and temporal proximity of a closely spaced second shock could terminate VF when the first shock did not. Conversely, if the first shock converted VF, a second shock could induce a relapse of the recently terminated arrhythmia.
    Different shock vectors affect different parts of the myocardium: Each shock from the surface of the chest sends current through the chest, resulting in variable current or energy delivered across the myocardium,23 depending on electrode positions, body habitus, and other factors. In parts of the heart where the electric field is strong enough, it interacts with myocytes to produce a desired effect (eg, to cause or extend refractoriness to VF). If an anterior‐lateral shock is inadequate for defibrillation, administering a second shock from a different vector shortly thereafter could provide an electric field strong enough in regions of the heart where the first shock was too weak to have the desired effect on myocytes,24 thereby enabling the therapy to affect a critical mass of myocardium.22, 25, 26
    Stepwise defibrillation, sometimes referred to as multistage electrotherapy: The first shock serves to decrease the complexity of the VF, reducing the defibrillation threshold so that the second shock is more likely to successfully terminate the arrhythmia.27, 28, 29
    Multiple observational experiences and systematic reviews published before the DOSE VF trial suggested that DSED may or may not be associated with significantly improved outcomes.30, 31, 32, 33 The largest systematic review included 10 studies that enrolled 1347 patients. Discussion highlighted the observational and heterogeneous nature of the individual studies incorporated into the systematic reviews, the variability of baseline characteristics and key definitions including what constituted “3 failed shocks” (successive versus total), and granularity defining “refractory” VF or down time before CPR or first shock delivered. In this context, the DOSE‐VF study provided the first randomized study design powered to detect a significant difference in outcome among patients with a pragmatic refractory VF definition.
    The DOSE‐VF trial was a cluster randomized trial with crossover among 6 EMS agencies in Canada. Included were adults with pragmatic refractory VF during OHCA, defined by the investigators as an initial shockable rhythm followed by the presence of VF after 3 consecutive shocks by paramedics. Treatment was according to 1 of 3 strategies randomly assigned in 6‐month periods to the paramedic service: (1) continued standard defibrillation, (2) VC defibrillation (switching pads to an anterior–posterior position), or (3) DSED. DSED patients received rapid sequential shocks from 2 defibrillators: one connected to the standard anterolateral electrodes and the second defibrillator to additional anterior–posterior electrodes. The primary outcome was survival to hospital discharge. Secondary outcomes included termination of VF, ROSC, and good neurologic outcome defined as modified Rankin scale score of ≤2 at hospital discharge. The trial was designed to enroll 930 patients (310 per arm) to have 80% power with 2‐sided α equal to 0.05 to detect an absolute difference in survival to discharge of 8% from a baseline survival of 12%.
    A total of 405 patients, 152 from the pilot trial34 and 253 from the main trial,4 were enrolled from March 2018 to May 8, 2022. Enrollment was paused on the recommendation of the data safety monitoring board from April 4 to September 8, 2020 because of difficulties implementing the trial during the COVID‐19 pandemic. The data safety monitoring board recommended termination of enrollment in the trial in May 2022 because pandemic‐related staffing shortages were associated with longer time to DSED application. A total of 136 patients were assigned to standard defibrillation, 144 to VC defibrillation, and 125 to DSED. The planned primary analysis was intention to treat. Survival to hospital discharge was significantly greater in the DSED group (adjusted relative risk [RR], 2.21 [95% CI, 1.33–3.67]) and in the VC group (adjusted RR, 1.71 [95% CI, 1.01–2.88]) as compared with the standard defibrillation group. Favorable neurologic outcome at discharge was significantly greater in the DSED group (RR, 2.21 [95% CI, 1.216–3.88]), but not in the VC group (RR, 1.48 [95% CI, 0.81–2.61]) as compared with the standard defibrillation group. The statistical analysis plan did not include comparison of outcomes between the DSED and the VC groups.
    The primary analysis of the DOSE VF trial was by intention to treat, which defines the benefits of the treatment strategy in clinical circumstances rather than the benefit of the device technology being studied per se. The median time interval between DSED shocks among participating EMS agencies before and during the DOSE VF trial was about 500 ms.35 When analyzed by treatment received, there were no significant differences in survival to discharge between patients who actually received DSED versus those actually treated with standard defibrillation (RR, 1.38 [95% CI, 0.90–2.11]) or between VC and standard defibrillation (RR, 1.13 [95% CI, 0.72–1.78]). When analyzed per protocol (ie, subject received treatment to which they were randomly allocated), these was a significant difference in survival to discharge between DSED and standard defibrillation (RR, 1.85 [95% CI, 1.08, 3.16]) but not between VC and standard defibrillation (RR, 1.57 [95% CI, 0.88, 2.81]). It was noted that the open label nature of the trial is susceptible to bias. As well, analyses by treatment received or per protocol should be interpreted with caution as they attenuate the effect of randomization. Most patients randomized to DSED but not treated with DSED “crossed over” due to logistical barriers to DSED delivery, such as location of arrest in a crowded room, bus or motor vehicle, on the side of a road, or in other tight quarters. In these situations, another standard shock was provided as the fourth (or subsequent) shock with apparent success. The baseline patient characteristics (eg, younger age, more public OHCA, shorter down time) and event characteristics (eg, amount of epinephrine, amount of antiarrhythmic drugs, number of shocks received) also differed between those who crossed over to standard care as compared with those who were randomized to standard care.
    The primary focus of the discussion was the effectiveness of DSED versus standard defibrillation. A comparison of DSED versus VC was not planned by the DOSE VF investigators for inclusion in the primary report of the trial results. A post hoc secondary analysis published after the thinktank reported that both DSED and VC reduced the duration of time in VF versus standard defibrillation.36 It was noted during the discussion that VC would be easier to implement and potentially require less time and be safer than DSED. Interest in future comparisons of single defibrillator versus dual defibrillator strategies, particularly given the logistical issues of finding and using 2 defibrillators in some OHCA settings, was discussed.
    There was discussion about the ramifications of early study interruption(s) on the reported findings. Enrollment ceased before intended balance in enrollment among clusters could be achieved. It was noted that termination of enrollment before a trial achieving its intended sample size may either exaggerate treatment effects37 or lack power and precision to detect treatment effects.
    Finally, it was discussed that outcomes after OHCA are affected by the number of providers on scene,38 EMS culture,39 and EMS provider experience and expertise.40 The primary report of the DOSE‐VF trial results suggests that EMS care was similar in each group including time from initial call to first shock, use of prehospital intubation, shock pause duration, quality of EMS CPR, time from EMS arrival to first antiarrhythmic drug administration. But no information was available about whether any imbalance in clusters (eg, EMS staffing) due to early cessation of enrollment might have impacted the trial results.
    The DOSE VF trial used a “pragmatic definition of refractory VF,” in agreement with 2005 AHA Guidelines to avoid interruption of high‐quality CPR in this setting. There was discussion about previously described mechanistic and clinical differences between “recurrent” and “refractory” VF. Published literature consistently suggests that refractory VF is associated with poorer outcomes, but is actually rare, whereas recurrent VF is common and often due to factors unrelated to the defibrillation itself (eg, ongoing myocardial ischemia, poor CPR quality) as opposed to true defibrillation failure that may in part implicate a problem with shock strategy or technology.
    A secondary analysis of the DOSE‐VF trial published after the thinktank reported data that were consistent with the previous literature.41 Of the pragmatic refractory VF patients enrolled in DOSE‐VF, 83% were identified as having recurrent rather than refractory VF. Regardless of treatment assignment, those with recurrent VF had a 3‐fold greater survival than those with refractory VF. A significant survival benefit was observed with DSED only in patients with persistent VF but not in those with recurrent VF. Note that the latter comparison had reduced power to detect a clinically important difference in outcome.
    Discussion noted that optimal therapeutic options during non‐VF periods in patients with recurrent VF could be quite different than in patients with true refractory VF. In the Resuscitation Outcomes Consortium ALPS (Amiodarone Lidocaine Placebo) trial,42 randomized antiarrhythmic drug therapy was given after the first shock to patients with OHCA and “refractory” VF, followed by another defibrillation attempt. It seems likely that many of the patients enrolled in the ALPS cohort were actually treated for recurrent VF pathophysiology. There is incomplete information about the benefit of antiarrhythmic drug therapy as compared with DSED.
    Discussion further focused on directions for future work that might add to current data and further clarify benefits and risks of DSED relative to other options for patients fitting the pragmatic definition of refractory VF used in the DOSE study. Key points of discussion included: Pragmatic prospective distinction of patient cohorts with refractory versus recurrent VF: Parallel limb lead monitoring or use of defibrillators with rhythm strip capability might add sufficient rhythm information during 2‐minute CPR windows immediately following defibrillation even with distortions from chest compressions. Study designs could promote more tailored approaches to therapeutic options to advance improved practices or support regulatory decisions facilitating innovative technologies designed for DSED.Direct comparison of DSED to other standard care therapy that could be protocolized for clinical studies of OHCA refractory and recurrent VF, including: Precision of pad positioningVector changeShock dose escalationImpedance modulation using direct manual pressure on defibrillation padsOptimization of vascular access and antiarrhythmic drug therapyDSED sequential timing interval randomization
    Pragmatic prospective distinction of patient cohorts with refractory versus recurrent VF: Parallel limb lead monitoring or use of defibrillators with rhythm strip capability might add sufficient rhythm information during 2‐minute CPR windows immediately following defibrillation even with distortions from chest compressions. Study designs could promote more tailored approaches to therapeutic options to advance improved practices or support regulatory decisions facilitating innovative technologies designed for DSED.
    Direct comparison of DSED to other standard care therapy that could be protocolized for clinical studies of OHCA refractory and recurrent VF, including: Precision of pad positioningVector changeShock dose escalationImpedance modulation using direct manual pressure on defibrillation padsOptimization of vascular access and antiarrhythmic drug therapy
    Precision of pad positioning
    Vector change
    Shock dose escalation
    Impedance modulation using direct manual pressure on defibrillation pads
    Optimization of vascular access and antiarrhythmic drug therapy
    DSED sequential timing interval randomization
    Establishing the safety and effectiveness of breakthrough therapies in high‐risk, vulnerable patients is likely to require randomized data to answer key questions for benefit/risk comparisons to standard care. But the effort, time, and cost required to enroll patients in multiple trials are challenging and could slow the advance of best‐practice knowledge and device innovation. High‐quality real‐world data sources for selected purposes may greatly augment this process in conjunction with trials as needed. Imbedding prospective randomized trials into real‐world infrastructure, such as high‐quality registries, could accelerate evidence‐based improvements in care.43, 44
    Multiple registries in the United States collate data to describe the process and outcome of care for patients with OHCA that could characterize the contemporary frequency of use of DSED. Apart from the ESO Data Collaborative mentioned earlier, other registries that could describe the process and outcome of DSED in patients with OHCA include the AHA’s GWTG‐R (Get With The Guidelines Resuscitation) and CARES (Cardiac Arrest Registry to Enhance Survival). GWTG‐R is an ongoing registry that collects both in‐hospital cardiac arrests and postcardiac arrest care from both in hospital and, more recently, OHCA. It was noted in discussion that some questions regarding DSED in OHCA might be more pragmatically explored with patients with in‐hospital CA, where logistical aspects of DSED use such as earlier response times, consistent pairings of defibrillators used, access to additional rhythm monitoring, physical space, and staffing might all be more consistent, and knowledge of comorbidities, concomitant medications, and other information more accessible. CARES is an ongoing EMS‐based registry that enrolls consecutive patients treated for OHCA.45 This registry could also be adapted to collect specific data regarding DSED in the out‐of‐hospital setting.
    Finally, another aspect of real‐world data sources included a focus on potential for global collaboration. The DOSE‐VF study conducted in Canada raises a spectrum of questions about generalizability to other nations, across regulatory jurisdictions, to minoritized populations, and to underresourced EMS agencies that do not have ready access to 2 defibrillators. Anecdotally, EMS systems that serve New Zealand as well as those that serve selected regions in Canada have adopted DSED as part of their standard practice. As of December 11, 2024, randomized trials of DSED are being planned in Denmark, Norway, Sweden, and Germany. Interoperable approaches to systematic international collection of high‐quality data from real‐world systems could also provide highly informative evidence for understanding best patients, best practices, and best device configurations through scientific collaborations.

    CRITICAL APPRAISAL OF THE TECHNICAL SCIENCE OF DSED FOR VF

    Contemporary defibrillators use biphasic energy waveforms and incorporate a range of software algorithms to diagnose the presence or absence of VF and energy settings. Devices intended for use in hospital and out of hospital by health care providers have varying degrees of manual override, and public access devices are automated to instruct users.
    Currently, no defibrillator is approved for clinical use to deliver rapid sequential shocks. Most EMS response vehicles do not carry 2 defibrillators. Thus, the technical logistics for OHCA may require medical staff to identify and deploy 2 defibrillators that are not designed to be used as a matched sequential or even synchronized pair. Whether a single operator triggers 2 devices, or whether 2 independent operators coordinate 2 triggers, human factors with manual approaches were considered likely to vary by around 250 ms in controlled laboratory settings.46 Greater variation would seem likely in real field settings treating OHCA.
    One key point of discussion was whether either the safety or effectiveness of DSED varied over a range of trigger timing intervals. Animal data suggest differences in the time interval between shocks is likely to affect effectiveness.47 Compared with 2 stacked shocks, dual shocks were more successful when overlapped within 7 ms, or when delivered precisely 10 or 100 ms apart. When the interval between shocks was greater than 200 ms, DSED had no significant benefit compared with two stacked single shocks. Notably, DSED was less effective than 2 stacked single shocks when the intershock interval was an intermediate 50 ms. There was speculation that there might be a window of time during the postshock period during which deleterious effects could affect myocytes, which are vulnerable to additional high‐dose energy. For recurrent VF, a second shock that is delivered after a successful first shock in a DSED sequence could be associated with refibrillation.48 It is unclear how these observations in controlled animal studies extrapolate to treatment of patients with VF in a clinical setting. These considerations cannot be confirmed or refuted at this time by either preclinical or clinical findings.
    In a post hoc analysis of patients who received DSED in participating EMS agencies before and during the DOSE VF trial, only a shock interval of less than 75 ms was associated with significantly greater termination of VF and ROSC.35 This secondary analysis removes randomization and is thus more susceptible to confounding.

    SAFETY CONSIDERATIONS

    Commerically manufactured defibrillators in the United States must meet thorough preclinical and clinical standards for evidence of material, engineering design, manufacture, performance, and labeling for clinical indications in populations of intended use. DSED constitutes a novel therapeutic approach deploying 2 defibrillators “off label” in rapid sequence or simultaneously. Prospective randomized data from the DOSE‐VF study meet its superiority primary outcome and point to the potential that this approach might offer a significant benefit to patients with refractory VF.
    In this context, it was recognized that no aspects of the use of any 2 defibrillators in rapid sequence have been considered in the initial design or manufacture of these devices by industry experts. Similarly, there has been no formal preclinical or clinical evaluation by experts from the FDA focused on the use of 2 defibrillators in rapid sequence.
    Discussion about the safety of DSED included acknowledgement that there were no safety signals reported from the DOSE‐VF randomized trial, but the early termination of the study reduced the overall sample size, making observation of low frequency but important adverse events less likely. For example, given the lack of reported subsequent device malfunction among the 125 patients randomized to receive DSED in the trial, the upper 95% confidence limit for device malfunction is estimable as 2.4%.49
    Using approved devices to perform a DSED intervention, safety considerations fell into three general categories including: Clinical outcomes relatedPersonnel relatedDevice related
    Clinical outcomes related
    Personnel related
    Device related
    Although the sole trial reported to date has not suggested harm to human subjects safety concerns persist. These include more subtle aspects of CPR interruption or delays in access to mechanical circulatory support, as well as the relatively small size of the trial. For instance, recognizing the significant proportion of the intention to treat group randomized to DSED who did not receive DSED, it is unclear how much field time was spent in unsuccessful attempts to aggregate or deploy the DSED strategy in small, crowded, challenging surroundings before deciding to move on. Finally, the post hoc observation that DSED benefit may be greater in truly refractory VF than in patients with recurrent VF the question as to whether the safety and efficacy of DSED differed in patients with refractory VF as compared with those with recurrent VF. The potential of alternative therapies such as VC compared with DSED was considered although there is less precise information about its safety and effectiveness, due to the small number of patients allocated to receive it in the DOSE VF trial and the analysis plan that did not include comparison of VC versus DSED outcomes.
    Personnel‐related safety issues were discussed mostly in the context of medical staff potentially getting shocked during application of the more complex sequential defibrillation processes that define DSED. This seems to be primarily an issue of relevant training for medical staff, with some subtleties. For instance if DSED were to be recommended exclusively for use for refractory VF by evidence‐based guidelines (ie, not for recurrent VF), it would be used relatively rarely in clinical care. Maintaining technical competence managing complex but rarely used techniques under urgent field circumstances may have risks, potentially more so for less experienced staff, etc.
    Device‐related safety refers to the defibrillator durability or the potential to cause defibrillator malfunction when 2 devices built to deliver standalone high energy shocks are used, and potentially used repeatedly, in overlapping or rapid sequence. Concerns discussed included the potential for the defibrillator to malfunction during the DSED intervention, as well as have an increased potential to fail when applied to a subsequent patient in VF. In the DOSE VF trial, 125 patients were allocated to DSED, which was too few to yield precise estimates of the risk of defibrillator malfunction. A survey of EMS medical directors and others reported a 0.4% rate of defibrillator damage among 1130 uses of DSED.50 All damaged devices were used with simultaneous discharge of another device. Damage was reported to be recognized immediately or with postuse testing rather than during subsequent clinical use.
    Discussion included comments from numerous manufacturers, whose field representatives were receiving a growing number of questions about use of their devices for DSED. As this use is off label, there are currently no manufacturer, FDA, or other authoritative recommendations specific to device appropriate use, checks, or maintenance in the context of DSED techniques. One manufacturer has provided information about the risks of DSED when using 2 of their devices including description of potential mitigations to minimize the risk of device damage. However, they have not commented on the risk of device damage if 2 different manufacturers’ devices are used as they do not have knowledge of the design of others’ devices.

    FUTURE DIRECTIONS FOR DSED THERAPY IN REFRACTORY VF OHCA

    Commensurate with the entire thinktank, participants’ discussion of future directions coalesced around 3 areas for further exploration: Clinical outcomes evidenceTechnical advances in DSED technique and technologyRegulatory pathways for DSED technology
    Clinical outcomes evidence
    Technical advances in DSED technique and technology
    Regulatory pathways for DSED technology
    Clinicians and patients previously recommended that studies of interventions in patients with OHCA should report survival outcomes to hospital discharge or 30 days after OHCA, neurologic function, or even health‐related quality of life post discharge.51, 52 But there is wide variation in hospital‐based postresuscitation care,53 and this care contributes significantly to survival.54 Although the ultimate goal of resuscitation is for a patient to have good health‐related quality of life, it may be desirable to evaluate the effect of field interventions upon more proximate outcomes that can be assessed in the field or early hospital period in order to obtain regulatory approval of DSED. Discussion was divided as to what regulatory science would be considered “tool claims” (eg, a defibrillator that defibrillates) from “surrogate outcomes” (eg, ROSC that may or may not singularly predict survival) from actual clinical outcomes (eg, mortality, health‐related quality of life). Consensus on a consistent approach to definitions for field, hospital, and postdischarge outcomes could greatly assist future evidence collection refining the role of DSED or other interventions focused on unmet needs of patients with OHCA and refractory VF.
    The need for technical advances in DSED technique and technologies was self‐evident throughout the thinktank presentations and discussion. Use of devices that are neither manufactured nor approved for an off‐label use such as DSED have issues with translating intention to treat into actual therapy. Field EMS time could be lost in setting up 2 defibrillators and coordinating the triggering if adoption of DSED is not implemented with sufficient training and monitoring. It could also burden EMS with doubling the cost and equipment requirements to implement care of patients with time‐sensitive refractory VF. Less clear is whether such applications shorten the lifespan of devices, also increasing costs for repair or replacement over time.
    Design and manufacturing features envisioned for devices with dedicated DSED capability included low‐profile single box, dual lead sets with automated DSED controls, dual capacitors to support two shocks, and digital precision cotriggering. However, for commercial manufacturers to develop even prototypes of such designs requires a dedicated research and development initiative, which at a minimum would imply (1) convincing clinical evidence of unique benefit of an integrated DSED device, (2) definition of the potential marketplace for such a device, and (3) clarity for the regulatory pathway requirements to bring such a device to commercial clinical use, including whether approval would be considered with a tool claim, a clinically relevant surrogate, or would require a clinical outcomes study. Noteworthy to these considerations is the recently launched Breakthrough Therapy designation,55 a fast‐track pathway with accelerated approval and priority review structures.
    Regulatory pathways for defibrillators are well established globally. In the United States, automated external defibrillators are regulated as Class III high risk devices. They are categorized based on their intended users and use environment as public access devices, over the counter, or professional (EMS or clinic/hospital based), although over time aspects of these categories are progressively converging. Current clinical evidence requirements for safety and effectiveness are based on the indications for the termination of VF and pulseless ventricular tachycardia. The population of intended use are victims of sudden cardiac arrest. The American National Standards Institute/Association for the Advancement of Medical Instrumentation/International Electrotechnical Commission 60601‐2‐4 standard defines basic technical standards of performance for these devices for delivering shock waveforms as a self‐standing system but does not provide any guidelines related to the development or testing of the effectiveness of a given waveform. Studies in porcine models of VF have been used to demonstrate performance, which typically include a study to demonstrate noninferiority to an approved shock waveform at minimum of 3 impedance levels (eg, 50, 85, 125 Ohms), and full energy to demonstrate first shock success at three impedance levels. Additionally, safety observations usually include demonstration of no statistically significant increase in myocardial injury as measured against an approved waveform. Other outcomes include termination of VF, ROSC, neurologic outcome, gross and microscopic pathology, troponin, creatine kinase myocardial band, etc. All current evaluation standards and evidence requirements are based on use of a single device.
    Although several of the requirements for testing single defibrillators might apply to DSED designs, FDA participants in the thinktank also noted how many aspects of this novel technology strategy would require early and thorough discussion with FDA staff. Based on the stipulations specified for the Breakthrough Technology designation, it would seem likely that a dedicated DSED defibrillator design might be included in such discussions.

    SUMMARY AND SCIENTIFIC RECOMMENDATIONS FOR NEXT STEPS

    After decades of observational reports, the DOSE‐VF study provides credible randomized data suggesting that DSED could offer significant benefits to patients with refractory VF. Breakthrough technologies are referred to as “disruptive” for many reasons, including the inevitable limitations, residual questions and particularly residual safety concerns about available data. A key effect in the “disruptive” moment includes the polarization of health care experts across a spectrum from enthusiastic early adopters to skeptics. Continuing a long tradition of fostering collaborative approaches to complex aspects of cardiovascular care, the AHA, the Cardiac Safety Research Consortium, and the FDA convened a collaborative community of clinician, industry, and regulatory experts across a spectrum of interpretations of available clinical, mechanistic, and logistical data on DSED, including the DOSE‐VF study. The daylong thinktank was not convened to provide conclusive answers, guidance, or guidelines on DSED. Rather the agenda was, through open discussion, intended to clarify and identify priority areas and approaches that could (1) provide direction to health care service professionals considering best and safest approaches to off‐label clinical use of DSED techniques, and (2) facilitate the advance of critical areas of further research beyond the DOSE VF study, to most directly and efficiently address key residual issues.
    Details on the scope of the presentations and discussion of this daylong meeting constitute the body of this report. Summarily here are listed the highest priority “forward looking” aspects of the discussion:
    New evidence‐based practice guidelines including DSED updated by the DOSE VF report will begin to emerge in 2025. Whether or not these guidelines change or even embrace the DSED option, they will certainly require refinement over time as new data emerge.
    Although some of the historical uncertainties about DSED were affected by the superior clinical outcomes reported in the DOSE VF trial, priority areas of ambiguity remain, in particular with respect to patient selection, optimal technical execution, optimal implementation and resources, and most of all safety concerns. Scientific recommendations discussed as priorities for future research include: Randomized trial design(s): DOSE VF was a cluster‐randomized trial, its small sample size across 3 treatment arms leave questions related to potential confounders to randomization and positive or negative bias to the results. A confirmatory trial with individual randomization to DSED versus standard care could be challenging to complete, but would provide the highest quality science to drive evidence‐based practice guidelines, or to provide industry and health systems impetus to move more innovative DSED protocols, training, and device designs into practice.Defining refractory VF: Scientifically, future confirmatory studies of any kind would best build on the DOSE VF report by using the identical inclusion criteria for refractory VF or pulseless VT, for example, “pragmatic refractory VF” after 3 previous shocks. One of the most repetitive areas of discussion was the concern that as defined in DOSE VF over 80% of patients were subsequently identified as having recurrent VF, consistent with historically reported OHCA VF epidemiology. As mechanistic substrates and clinical outcomes are known to significantly vary, the possibility that overuse of DSED in recurrent VF might have less benefit and even potential for harm represents a high‐priority safety concern. Scientifically, the use of the DOSE VF trial’s pragmatic refractory VF definition should be augmented by ancillary rhythm monitoring to distinguish refractory from recurrent VF, and the statistical analysis plan should consider outcomes in the whole cohort with a prospectively identified secondary analysis specific to each of the subgroups. The latter are likely to be underpowered but still informative to safety concerns.
    Randomized trial design(s): DOSE VF was a cluster‐randomized trial, its small sample size across 3 treatment arms leave questions related to potential confounders to randomization and positive or negative bias to the results. A confirmatory trial with individual randomization to DSED versus standard care could be challenging to complete, but would provide the highest quality science to drive evidence‐based practice guidelines, or to provide industry and health systems impetus to move more innovative DSED protocols, training, and device designs into practice.
    Defining refractory VF: Scientifically, future confirmatory studies of any kind would best build on the DOSE VF report by using the identical inclusion criteria for refractory VF or pulseless VT, for example, “pragmatic refractory VF” after 3 previous shocks. One of the most repetitive areas of discussion was the concern that as defined in DOSE VF over 80% of patients were subsequently identified as having recurrent VF, consistent with historically reported OHCA VF epidemiology. As mechanistic substrates and clinical outcomes are known to significantly vary, the possibility that overuse of DSED in recurrent VF might have less benefit and even potential for harm represents a high‐priority safety concern. Scientifically, the use of the DOSE VF trial’s pragmatic refractory VF definition should be augmented by ancillary rhythm monitoring to distinguish refractory from recurrent VF, and the statistical analysis plan should consider outcomes in the whole cohort with a prospectively identified secondary analysis specific to each of the subgroups. The latter are likely to be underpowered but still informative to safety concerns.
    Clarification and consensus of how to best define VF that is observed after initial provider assessment are warranted. “Refractory VF” had a pragmatic definition in the DOSE VF trial. But “refractory” is often taken to imply unsuccessful defibrillation (ie, shock refractoriness), whereas VF seen 2 minutes after shock could represent true refractory VF (ie, incessant VF due to unsuccessful defibrillation), recurrent VF (ie, VF that returned after successful defibrillation), or an alternating mix of the 2 during the course of more than 3 successive shocks. An alternative term such as “persistent VF” may be preferable to “refractory” when VF is seen upon interruption of CPR, because this avoids implying a specific mechanism for its appearance. “Persistent” could simply means it is still observed, without implying system (ie, shock) failure. 3Optimizing control arm(s): Discussion repeatedly pointed to both continued defibrillation beyond 3 shocks and to VC as currently clinically accepted or “control” strategies. The DOSE VF study’s statistical analysis plan compared DSED to control and VC to control but not VC to DSED. The DSED technique includes adding the anteroposterior vector as a part of the intervention. In the DOSE VF study, even with the reduced cohort size, the VC arm appeared to do better than the single vector control arm. In future studies, comparison of DSED, which logistically requires 2 defibrillators and special training, to VC, which does not, would scientifically inform this arena.
    Optimizing control arm(s): Discussion repeatedly pointed to both continued defibrillation beyond 3 shocks and to VC as currently clinically accepted or “control” strategies. The DOSE VF study’s statistical analysis plan compared DSED to control and VC to control but not VC to DSED. The DSED technique includes adding the anteroposterior vector as a part of the intervention. In the DOSE VF study, even with the reduced cohort size, the VC arm appeared to do better than the single vector control arm. In future studies, comparison of DSED, which logistically requires 2 defibrillators and special training, to VC, which does not, would scientifically inform this arena.
    Registries or other commercial or private health care systems that gather complete national, regional, state, or hospital networks data on OHCA constitute infrastructure for understanding the uptake of novel interventions within the actual denominator of relevant clinical encounters. Such systems that actively monitor the missingness and accuracy of their data may aggregate high‐quality data sets that are suitable for statistical analyses, transforming such real‐world data into real world evidence. Real‐world infrastructure may provide uniquely informative and efficient means to aggregating evidence in more rare patient conditions that may challenge classical prospective trial efforts—for instance patients with OHCA with truly refractory VF. Real‐world infrastructure such as professional society registries may also provide unique efficiencies, high quality, and faster patient enrollment access (in addition to diversity and inclusiveness enhancements) to ease the site and the sponsor burden of prospective trials by imbedding them into the registry infrastructure. Professional society registries often include data portals in research site hospitals, which could facilitate DSED research areas that might benefit from the more controlled setting of inpatient hospital use of DSED. Finally, interoperability across real‐world infrastructure platforms could support a uniquely practical means to engage in international collaborative DSED research efforts.
    The logistics of DSED use were widely recognized as impactful on clinical evidence development efforts. Most crossovers in DOSE VF were attributed to inability to execute DSED in a variety of field scenarios. This could imply the relative impracticality of such an approach in clinical practice. The divergence between the significant benefit observed in intention to treat analysis, and the lack of benefit observed in the as treated analysis spawned a variety of conflicting interpretations. The least ambiguous of these is the need for technical capabilities that better support DSED protocol compliance. In addition to the protocol compliance issue, variability of brands and models of commercially available defibrillators that are used for OHCA VF DSED use have potential incompatibility issues that range from combinations producing ineffective DSED waveform sequencing to residual safety concerns.
    DSED technique as currently practiced represents an “off‐label” use of 2 commercially approved defibrillators by a clinician who considers it to be in the best interest of a patient and who has the right to do so as the “practice of medicine.” The FDA does not regulate the practice of medicine. However, manufacturers cannot advertise, sell, modify, advise, or redesign commercially available devices for off‐label use. Two examples of pathway variations for DSED might include (1) identifying the “prototype” as a pair of discrete, currently manufactured and approved defibrillators, where bench and preclinical testing and ultimately human subjects research might constitute a scientifically sound submission to FDA to justify an instructions for use “label extension” for DSED deployment in patients with refractory VF, or (2) to create a dedicated single box, dual capacitor dual cable device prototype, test it on the bench and in animals, and inquire of FDA regarding the potential to pursue this device with a breakthrough technology designation expedited pathway. For these or any other defibrillator‐related innovation, early interaction with FDA directly would be a recommended step.

    Sources of Funding

    The Double Sequential Defibrillation Thinktank was funded by the American Heart Association.

    Disclosures

    Graham Nichol discloses research funding from Patient Centered Outcomes Research Institute (Washington, DC), Abiomed Inc. (Danvers, MA), ZOLL Medical Corp. (Chelmsford, MA), and is a member of the steering committee of the PRINCESS 2 Trial of Ultrafast Hypothermia After Cardiac Arrest. He is also a consultant to Orixha Inc. (Saint Cyr Au Mont d’Or, France) and Celecor Inc. (Del Mar CA). Dianne L. Atkins is a member of the data‐safety monitoring board for the NIH‐funded Pediatric Heart Network. Douglas F. Kupas reported that he is a member of the board of the Cardiac Arrest to Enhance Survival Registry. The remaining authors have no disclosures to report.
    CS

    Dr. Comilla Sasson

    Emergency Medicine · General Emergency Medicine
    University of Colorado Anschutz
    comilla